Twist Bioscience (NASDAQ:TWST) Stock Price Up 9% – Here’s Why

12 Jan 2026, 22:32 by Danessa Lincoln · The Markets Daily

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) traded up 9% on Monday . The stock traded as high as $39.23 and last traded at $38.50. 268,449 shares were traded during trading, a decline of 78% from the average session volume of 1,213,133 shares. The stock had previously closed at $35.32.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on TWST shares. Barclays raised their price objective on Twist Bioscience from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Evercore ISI restated an “outperform” rating and issued a $42.00 price target on shares of Twist Bioscience in a research note on Monday, January 5th. Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Thursday. Stephens began coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Finally, TD Cowen upped their price target on shares of Twist Bioscience from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday. Nine investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.67.

Read Our Latest Analysis on TWST

Twist Bioscience Stock Performance

The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of -29.04 and a beta of 2.19. The company has a 50 day moving average price of $31.49 and a 200 day moving average price of $31.10. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.33 and a current ratio of 3.64.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%.The firm had revenue of $99.01 million during the quarter, compared to the consensus estimate of $97.40 million. Equities research analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Activity

In other Twist Bioscience news, CFO Adam Laponis sold 5,517 shares of the business’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $31.44, for a total transaction of $173,454.48. Following the completion of the sale, the chief financial officer directly owned 111,008 shares of the company’s stock, valued at approximately $3,490,091.52. The trade was a 4.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dennis Cho sold 6,515 shares of the stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $204,831.60. Following the completion of the sale, the insider owned 121,713 shares of the company’s stock, valued at approximately $3,826,656.72. This represents a 5.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 60,699 shares of company stock valued at $1,919,823. 3.01% of the stock is currently owned by insiders.

Institutional Trading of Twist Bioscience

Several hedge funds have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock valued at $95,883,000 after acquiring an additional 1,588,587 shares in the last quarter. Strs Ohio purchased a new position in Twist Bioscience in the 1st quarter worth approximately $711,000. American Century Companies Inc. increased its holdings in shares of Twist Bioscience by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 864,384 shares of the company’s stock worth $31,801,000 after buying an additional 100,978 shares during the last quarter. Conestoga Capital Advisors LLC bought a new stake in Twist Bioscience during the second quarter worth about $1,044,000. Finally, Squarepoint Ops LLC lifted its position in Twist Bioscience by 192.8% in the 2nd quarter. Squarepoint Ops LLC now owns 71,708 shares of the company’s stock worth $2,638,000 after buying an additional 47,221 shares during the last quarter.

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.